<DOC>
	<DOCNO>NCT00617851</DOCNO>
	<brief_summary>The purpose research demonstrate immunologic equivalence three consecutive production lot subunit influenza vaccine compare egg-derived inactivated influenza vaccine healthy subject 18 49 year ages . In addition , study show safe well tolerated conventional inactivated subunit influenza vaccine , license many country outside United States , compare inactivated influenza vaccine , license United States .</brief_summary>
	<brief_title>Study Evaluate Consistency Three Consecutive Production Lots Influenza Vaccine Healthy Subjects 18 49 Years Old</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>18 49 year age ; In good health determine medical history physical examination ; Able willing provide write informed consent prior study procedure ; Able comply study procedure available clinic visit schedule study . Any serious disease , : cancer , autoimmune disease ( include rheumatoid arthritis ) , advance arteriosclerotic disease complicate diabetes mellitus History anaphylaxis , serious vaccine reaction , hypersensitivity egg , egg protein , chicken feather , influenza viral protein , neomycin , polymyxin , vaccine component , chemically related substance , component potential packaging material ( latex ) ; Known suspected impairment/alteration immune function Receipt influenza vaccine within 6 month prior Visit 1 ; Current drug alcohol abuse history drug alcohol abuse investigator 's opinion would interfere safety subject evaluation study objective ; Laboratoryconfirmed influenza disease within 6 month prior Visit 1</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Influenza</keyword>
	<keyword>adult</keyword>
	<keyword>different lot</keyword>
	<keyword>trivalent subunit influenza virus vaccine ( IVV )</keyword>
	<keyword>trivalent subunit influenza vaccine</keyword>
</DOC>